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Background: While it is known that CD123 is normally strongly expressed on plasmacytoid dendritic cells
and completely absent on nucleated red blood cells, detailed information regarding CD123 expression in acute
leukemia is scarce and, if available, hard to compare due to different methodologies.
Methods: CD123 expression was evaluated using standardized EuroFlow immunophenotyping in 139 pediat-
ric AML, 316 adult AML, 193 pediatric BCP-ALL, 69 adult BCP-ALL, 101 pediatric T-ALL, and 28 adult T-ALL
patients. Paired diagnosis-relapse samples were available for 57 AML and 19 BCP-ALL patients. Leukemic
stem cell (LSC) data was available for 32 pediatric AML patients. CD123 expression was evaluated based on
mean ﬂuorescence intensity, median ﬂuorescence intensity, and percentage CD123 positive cells.
Results: EuroFlow panels were stable over time and between laboratories. CD123 was expressed in the
majority of AML and BCP-ALL patients, but absent in most T-ALL patients. Within AML, CD123 expression was
lower in erythroid/megakaryocytic leukemia, higher in NPM1 mutated and FLT3-ITD mutated leukemia, and
comparable between LSC and leukemic blasts. Within BCP-ALL, CD123 expression was higher in patients with
(high) hyperdiploid karyotypes and the BCR-ABL fusion gene. Interestingly, CD123 expression was increased in
BCP-ALL relapses while highly variable in AML relapses (compared to CD123 expression at diagnosis).
Conclusions: Authors evaluated CD123 expression in a large cohort of acute leukemia patients, based on stan-
dardized and reproducible methodology. Our results may facilitate stratiﬁcation of patients most likely to respond to
CD123 targeted therapies and serve as reference for CD123 expression (in health and disease). © 2018 The Authors.
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The interleukin-3 receptor alpha chain (IL-3Rα),
more commonly referred to as CD123, is normally
strongly expressed on plasmacytoid dendritic cells
(PDC) and completely absent on nucleated red blood
cells (NRBC). Others have shown that CD123 is widely
expressed in various hematological malignancies as
well (1), including acute myeloid leukemia (AML) and
B cell precursor acute lymphoblastic leukemia (BCP-
ALL). Most notably, it was also shown that CD123 is
expressed on both leukemic stem cells (LSC) as well as
more differentiated leukemic blasts in both AML and
BCP-ALL, which makes CD123 an attractive therapeutic
target (2).
At present, various CD123 therapeutic monoclonal
antibodies have entered clinical trials (3). One of these
trials is based on the CD123 antibody drug conjugate
SGN-CD123A, where the pyrrolobenzodiazepine toxin
was coupled to a CD123 speciﬁc antibody (3), leading to
targeted drug delivery. Another monoclonal antibody is
Talacotuzumab, which was the ﬁrst CD123 therapeutic
monoclonal antibody to enter phase-III clinical trials.
Talacotuzumab is a fully humanized CD123-neutralizing
monoclonal antibody containing a modiﬁed Fc structure,
which enhances human natural killer cell antibody-
dependent cell-mediated cytotoxicity, and thereby facili-
tates lysis of CD123 positive cells.
By targeting a therapeutic monoclonal antibody to
the interleukin-3 receptor alpha chain (CD123), it may
block processes regulated by the IL-3 receptor itself,
including cell survival, proliferation, and differentiation
(4). Efﬁcacy of CD123 targeted therapies in acute leuke-
mia is likely to correlate with CD123 expression of leu-
kemic cells, as was shown for other targeted therapies.
For example, the response to Daratumumab (CD38 tar-
geting therapy) and Gemtuzumab Ozogamicin (CD33
targeting therapy) correlates with CD38 expression and
CD33 expression of leukemic cells, respectively (5,6).
Unfortunately, detailed information regarding CD123
expression in acute leukemia is scarce and, if available,
hard to compare between studies due to different meth-
odologies. In this study, we extensively evaluated
846 acute leukemia patients (at diagnosis and at
relapse) and 1,736 normal leukocyte populations using
highly standardized immunophenotyping protocols and
robust statistical analysis. Our data provide a unique
insight in CD123 expression (in both health and dis-
ease) and may support identiﬁcation of patients most
likely to beneﬁt from novel CD123 targeting therapies.
METHODS
Materials
Acute leukemia patients (n = 846) were retrospec-
tively selected based on availability of relevant ﬂow
cytometric data (thus at least one CD123 staining
acquired at date of initial diagnosis). Patients were
either evaluated by the Dutch Childhood Oncology
Group (DCOG) or the Department of Immunology at
Erasmus MC (EMC). Included patients were classiﬁed
according to the WHO 2008 classiﬁcation (7) and con-
sisted of 139 pediatric AML, 316 adult AML, 193 pediat-
ric BCP-ALL, 69 adult BCP-ALL, 101 pediatric T-ALL
and 28 adult T-ALL patients. Included patients origi-
nated from two cohorts of unselected consecutive
patients, the pediatric DCOG cohort (initial diagnosis
between February 2011 and July 2016) and the pediat-
ric/adult EMC cohort (initial diagnosis between January
2011 and December 2016). Detailed cohort characteris-
tics, including age distributions, are available for the
EMC cohort, DCOG cohort and combined EMC-DCOG
(Supporting Information 1). In addition to the initial
diagnostic samples, paired relapse samples were avail-
able for 57 of the 455 AML patients and 19 of the
262 BCP-ALL patients. LSC ﬂow cytometry data was
available for 32 out of 56 pediatric AML cases from the
EMC cohort. Evaluated patients did not receive
CD123-targeted therapy prior to immunophenotyping.
In addition to leukemic cell populations, a total of 1736
normal cell populations were identiﬁed in 1,252 unique
bone marrow (BM) and peripheral blood (PB) samples.
Normal cell populations were either identiﬁed in sam-
ples that were considered normal during diagnostic
evaluation and/or samples where the lineage of interest
was not affected by disease (e.g., normal lymphocytes
in AML and eosinophils in T-ALL). Besides normal PDC
(n = 198) and NRBC (n = 633), which served as nega-
tive and positive control populations, also normal
eosinophils (n = 67), neutrophils (n = 169), mature B-
lymphocytes (n = 174), T-lymphocytes (n = 404), and
basophils (n = 91) were identiﬁed. All samples and
resulting datasets were collected according to local
Medical Ethics Committee guidelines (METC-2007-234).
Immunophenotyping
For each sample, standardized EuroFlow immuno-
phenotyping was performed by either DCOG labora-
tory or EMC laboratory, both EuroFlow members
participating in the EuroFlow Quality Assurance Pro-
gram (8) and the Dutch Quality Assurance Program (9).
Staining and acquisition procedures were performed
according to EuroFlow guidelines (10) and ﬂow cyto-
metry was performed on FACSCanto II ﬂow cytometers
(BD, Erembodegem, Belgium) with EuroFlow instru-
ment settings (11). Instrument performance was moni-
tored on a daily basis using CS&T beads and rainbow
beads (11,12). BM, PB, lymph node (LN), or pleural
effusion (PE) samples were used for immunophenotyp-
ing. Samples were processed within 36 h as part of rou-
tine diagnostic evaluation and at least 50,000 events
were acquired. (Pre-)analytical procedures were identi-
cal for both laboratories. Included AML, BCP-ALL, and
T-ALL patients were evaluated with the EuroFlow
AML/MDS panel, EuroFlow BCP-ALL panel, and Euro-
Flow T-ALL panel, respectively. Each EuroFlow panel
contains one eight-color labeling (Supporting Informa-
tion 2) with CD123 clone AC145 conjugated with the
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APC ﬂuorochrome (Miltenyi Biotec, Bergisch Gladbach,
Germany), allowing direct comparison of CD123
expression levels. Manual analysis was performed on a
single tube basis using Inﬁnicyt software (Cytognos,
Salamanca, Spain). Using available markers, the vast
majority of malignant populations were clearly distin-
guishable (Supporting Information 3). Overlapping and
doubtful malignant populations (mainly AML cases)
were successfully gated by referring to the routine diag-
nostic evaluation (based on the full EuroFlow panel).
Gating strategies were different for each hematological
malignancy, but never included any CD123 gates. Nor-
mal populations were only included in cases where
they were clearly distinguishable and presented with a
normal immunophenotype (Supporting Information 4).
Detailed information regarding the LSC assay was pre-
viously published and a similar gating strategy was
used (Supporting Information 5).
Assay Stability
Assay stability was evaluated in 633 normal NRBC
populations (as negative reference) and 198 normal
PDC populations (as positive reference). To evaluate
assay stability over time, between laboratories and
across panels, the normal NRBC and PDC were
grouped by acquisition year, acquisition laboratory,
and/or acquisition panel. Subsequently, the groups
were evaluated for differences in variance and
distribution.
Statistical Analysis
CD123 median ﬂuorescence intensity (CD123-MFI)
and percentage CD123 positive cells (CD123-PPC) were
used as measurement for CD123 expression. Cut-off for
CD123 positivity was deﬁned as the highest 98th per-
centile found among all 633 normal NRBC populations.
Impact of the chosen CD123 positivity cut-off was eval-
uated by repeating statistical analysis based on various
(arbitrarily chosen) lower and higher positivity cut-offs.
Impact of using median instead of mean ﬂuorescence
intensity was evaluated as well. Mann–Whitney U tests
(two tailed signiﬁcance, paired where appropriate)
were used to compare the means of two subgroups. In
case of numerous comparisons, means of subgroups
were compared using one-way analysis of variance
(ANOVA). Brown–Forsythe test, Fligner-Killeen test,
and Barlet test were used to evaluate homogeneity of
variances of multiple subgroups. Pearson correlation
coefﬁcient was used as measurement for linear correla-
tion and Spearman’s rank correlation coefﬁcient was
used as measure for rank correlation.
Relationship between two variables was considered
signiﬁcant when both Pearson’s and Spearman’s coefﬁ-
cient were signiﬁcant. Interpretation of results was per-
formed at an alpha level of 0.05 after applying
Bonferroni multiple testing corrections where appropri-
ate. Statistical analysis was performed in R base (ver-
sion 3.4.1) with the Car library for variance testing
(version 2.1.4) and the FlowCore library for extraction,
compensation, and transformation of manually gated
FCS ﬁles (version 1.42.2).
RESULTS
Assay Stability
Normal NRBC and PDC populations were identiﬁed
in samples acquired at different time points
(2011–2016), in different laboratories (DCOG or EMC)
and using different panels (EuroFlow AML/MDS, BCP-
ALL, and T-ALL). Resulting populations were grouped
by year and laboratory to evaluate assay stability over
time and across laboratories (Fig. 1). Overall compari-
son of the subgroups (using ANOVA, Brown–Forsythe,
Fligner-Killeen, and Barlet) revealed no signiﬁcant dif-
ferences (always P > 0.05). Comparison of individual
subgroups versus the remainder of subgroups together
(using Mann–Whitney U with Bonferroni correction)
revealed no signiﬁcant differences as well. Therefore,
there was no statistical evidence to suggest that the
NRBC subgroups or PDC subgroups have different dis-
tributions and/or variances. Grouping the populations
by year and by panel showed no signiﬁcant differences
as well (Supporting Information 6). Overall, these data
indicated that the applied CD123 assay was stable and
reproducible for the duration of the study (over time
and across laboratories).
Positivity Cut-Off
Evaluated normal NRBC populations were used to
determine the cut-off for CD123 positivity. CD123 posi-
tivity cut-off was deﬁned as the highest 98th percentile
found among all normal NRBC populations. Based on
this positivity cut-off, located at 739 intensity (Fig. 1),
only low numbers of NRBC were identiﬁed to be
CD123 positive (less than 2% positive cells within all
NRBC populations and even less than 1% positive cells
within 95% of NRBC populations). Various arbitrary
intensity cut-offs (700, 800, 900, and 1000) were evalu-
ated as well (Supporting Information 7). For each arbi-
trary cut-off, the highest percentage CD123 positive
cells (found among all NRBC populations) was still low
(2.4, 1.7, 1.6, and 1.5%, respectively). During this study,
CD123 positivity was evaluated based on the 739 inten-
sity cut-off (as it was objectively deﬁned) and evaluated
based on the 1,000 intensity cut-off (to make sure our
results were not inﬂuenced by CD123 false-positive
events).
CD123-MFI in Normal Cells
Average CD123 expression levels, as measured by
CD123 median ﬂuorescence intensity (CD123-MFI), were
visualized for each normal and malignant population on
a default logical scale (Fig. 2A). As expected, compared
to any other normal and abnormal population,
CD123-MFI was lowest in NRBC (P < 0.001) and highest
in PDC (P < 0.001). Other evaluated normal populations
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showed signiﬁcant different CD123-MFI levels as com-
pared to each other (P < 0.001), where CD123-MFI was
lowest in T-cells and increasingly higher in mature B-
cells, granulocytes, eosinophils, and basophils. Within all
evaluated normal populations CD123 expression was
homogeneous. CD123 expression was also evaluated in a
APC:CD123 MFI (mean)
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FIG. 1. Assay stability over time (2011–2016) and across laboratories (EMC and DCOG). Evaluation based on normal NRBC and normal PDC
(as negative and positive control, respectively). Visualization per individual population, where the horizontal gray bars visualize the 96% interval and the
vertical black bars visualize the median CD123 expression (CD123-MFI). Solid vertical line indicates the highest 98 percentile found among all NRBC
populations, which was used as positivity cut-off during CD123-PPC analysis. For each subgroup, the Wilcoxon signed-rank test result is shown,
comparing the subgroup against the remainder of populations (Wp denotes the probability value after Bonferroni correction). One-way ANOVA did not
reveal any signiﬁcant differences among the NRBC and PDC subgroups as well (both tests P > 0.05). The Bartlett test, Fligner-Killeen test, and Brown–
Forsythe tests, comparing all PDC subgroups at once, did not reveal any signiﬁcant differences as well (P = 0.154, P = 0.065, P = 0.075, respectively).
In conclusion, evaluated subgroups have comparable distributions and variances, conﬁrming assay stability over time and across centers.
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FIG. 2. CD123 median ﬂuorescence intensity (CD123-MFI) for normal mature leukocyte subsets and acute leukemia. Curved gray lines visualize
Gaussian kernel density estimation. Vertical gray bars visualize performed Wilcoxon signed-rank tests (P-value after Bonferroni multiple testing
correction was smaller than 0.001 unless otherwise speciﬁed). (A) CD123-MFI for AML, BCP-ALL, and T-ALL patients and various normal populations.
Vertical dotted line represents the highest CD123-MFI among evaluated NRBC populations. (B) CD123-MFI levels for selected AML subgroups. (C)
CD123-MFI levels for selected BCP-ALL subgroups.
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limited set of normal myeloid and B-cell precursors.
CD123-MFI was low in CD34-positive BCP, higher in
CD34-negative BCP (P < 0.001) and highest in
CD34-positive myeloid precursors (P < 0.001; Supporting
Information 8), in line with literature (13).
CD123-MFI in Malignant Cells
CD123-MFI was low in T-ALL although signiﬁcantly
higher compared to NRBC (Fig. 2A). In contrast,
CD123-MFI was high in AML and BCP-ALL compared to
NRBC (Fig. 2A). Only 2% of AML cases (11/455) and
15% of BCP-ALL cases (38/262) showed lower
CD123-MFI than the highest CD123-MFI observed
among all normal NRBC populations (dotted verti-
cal line).
Pediatric BCP-ALL cases had signiﬁcantly higher
CD123-MFI while pediatric T-ALL cases had signiﬁ-
cantly lower CD123-MFI compared to their adult coun-
terparts (Fig. 2A). T-ALL patients with notable high
CD123-MFI did not have any obvious characteristics in
common (including immunophenotypic maturation
stage and/or being early T-cell precursor T-ALL). No
signiﬁcant difference in CD123-MFI was present
between pediatric and adult AML (Fig. 2A). In addition,
continuous analysis (Supporting Information 9)
revealed that age negatively correlated to CD123-MFI in
BCP-ALL, positively correlated to CD123-MFI in T-ALL
and did not correlate to CD123-MFI in AML. Although
signiﬁcant these age correlations are weak and likely
clinical irrelevant.
Relation between CD123-MFI and WHO 2008 classiﬁ-
cation was evaluated for BCP-ALL and AML patients.
Within AML, CD123-MFI was signiﬁcantly lower in
patients with the erythroid or megakaryocytic lineage
affected and signiﬁcantly higher in patients with a
mutated NPM1 (Fig. 2B). FLT3-ITD positive AML
patients had signiﬁcant (P < 0.001) higher CD123-MFI
as compared to FLT3-ITD negative AML patients
(Supporting Information 9). Increased CD123-MFI
expression in NPM1 patients was not caused by co-
existing FLT3-ITD (as the majority of these patients
were FLT3-ITD negative). Within BCP-ALL CD123-MFI
was signiﬁcantly higher in (high) hyperdiploid patients
and patients with the BCR-ABL1 fusion gene (Fig. 2C).
Other genetic characteristics did not relate to
CD123-MFI in AML and BCP-ALL (Supporting Informa-
tion 10).
CD123-PPC in Malignant Cells
Next the percentage of CD123-positive cells based on
the 739 positivity cut-off (CD123-PPC) was evaluated
for AML patients, BCP-ALL patients, and T-ALL patients
(Fig. 3A). CD123-PPC was highest in AML, lower in
BCP-ALL, and lowest in T-ALL (all comparisons
P < 0.001). At least 80% of leukemic cells were CD123
positive in approximately 55% of AML patients and 30%
of BCP-ALL patients. Pediatric BCP-ALL patients
showed signiﬁcantly higher CD123-PPC while pediatric
T-ALL cases showed signiﬁcantly lower CD123-PPC
compared to their adult counterparts (P < 0.01). No sig-
niﬁcant difference in CD123-PPC was observed
between pediatric and adult AML. Continuous analysis
(Supporting Information 11) revealed that age was neg-
atively correlated to CD123-PPC in BCP-ALL and posi-
tively correlated to CD123-PPC in T-ALL. Relation
between CD123-PPC and WHO 2008 classiﬁcation was
evaluated for BCP-ALL and AML patients. Within AML,
the CD123-PPC was signiﬁcantly lower in patients with
the erythroid or megakaryocytic lineage affected and
signiﬁcant higher in patients with a mutated NPM1
(Fig. 3B). Within BCP-ALL, the CD123-PPC was signiﬁ-
cantly higher in (high) hyperdiploid patients and
patients with the BCR-ABL1 fusion gene (Fig. 3C).
CD123-PPC was signiﬁcantly higher in FLT3-ITD posi-
tive AML patients (P < 0.001). Other genetic characteris-
tics did not relate to CD123-PPC in AML and BCP-ALL
(Supporting Information 12). In conclusion, results
based on CD123-PPC were comparable to the results
based on CD123-MFI.
CD123-MFI in Relapses and LSC
Paired diagnosis-relapse samples were evaluated for
19 BCP-ALL patients and 57 AML patients. Within BCP-
ALL, the overall CD123-MFI levels were signiﬁcantly
higher at relapse as compared to diagnosis, with only
3 out of 19 patients showing slightly lower CD123
expression at relapse (Fig. 4A). Within AML, the overall
CD123-MFI levels (diagnosis vs. relapse) were not sig-
niﬁcantly different (Fig. 4B). However, within AML the
CD123-MFI levels on a per patient basis were highly
variable between diagnosis and relapse, showing either
signiﬁcant gains or losses. Observed CD123 gains and
losses did not appear to be caused by CD123 negative
and/or positive subclones as the vast majority featured
unimodal CD123 distributions (Supporting Information
13). Gains and losses did not correlate to WHO classiﬁ-
cations and/or time-till-relapse (Supporting Informa-
tion 14).
Within AML, the CD123-MFI of LSC (deﬁned as the
CD34 positive and CD38 negative fraction of leukemic
blasts) was highly comparable to CD123-MFI of non-
LSC (deﬁned as the remainder of the leukemic blasts).
The vast majority of LSC and non-LSC populations fea-
tured a unimodal CD123 distribution (Supporting Infor-
mation 15).
Robustness
CD123 expression was evaluated based on two dis-
tinct measurements; average CD123 expression
(as measured by CD123 median ﬂuorescence intensity,
referred to as CD123-MFI) and the number of CD123
positive cells (as measured by percentage CD123 posi-
tive cells based on 739 intensity cut-off, referred to as
CD123-PPC). Statistical analysis based on CD123-MFI
and CD123-PPC resulted in identical conclusions.
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Average expression is typically measured by either
mean or median ﬂuorescence intensity, which poten-
tially inﬂuences results. Although expression patterns
generally seemed to be normally distributed, statistical
tests based on CD123 median ﬂuorescence intensity
values were repeated based on CD123 mean ﬂuores-
cence intensity values; this resulted in identical conclu-
sions (Ext Supporting Information 1).
0 10 20 30 40 50 60 70 80 90 100
0
10
20
30
40
50
60
70
80
90
10
0
ACUTE LEUKEMIA
APC:CD123−PPC (cut−off at 739)
P
er
ce
n
ta
g
e 
P
at
ie
n
ts
Pediatric
Adult
AML p=0.270
BCP−ALL p=0.000
T−ALL  p=0.000
0
(A) (B)
(C)
10 30 50 70 90
0
25
50
75
10
0
AML − SUBGROUPS
APC:CD123−PPC (cut−off at 739)
P
er
ce
n
ta
g
e 
P
at
ie
n
ts
NPM1
Other
Erythroid
Megakaryocytic
0 10 30 50 70 90
0
25
50
75
10
0
BCP−ALL − SUBGROUPS
APC:CD123−PPC (cut−off at 739)
P
er
ce
n
ta
g
e 
P
at
ie
n
ts High Hyperdiploid
Hyperdiploid
t(9;22)
Other
FIG. 3. Percentage CD123 positive cells (CD123-PPC) for AML, BCP-ALL, and T-ALL patients. Percentage CD123 positive cells based on
739 intensity cut-off. Black lines visualize pediatric patients and gray lines visualize adult patients. Gray area visualizes the difference between
pediatric and adult patients (reported P-values based on a Mann–Whitney U tests). Other immunophenotyping studies typically state “at least …
patients have at least … percent positive cells.” As different studies use different percentages, we have chosen for this visualization, which allows
lookup of any combination. For example, approximately 65% of pediatric AML patients have at least 60% CD123 positive cells based on the
739 positivity cut-off. (A) CD123-PPC for AML, BCP-ALL and T-ALL patients. (B) CD123-PPC for selected AML subgroups. (C) CD123-PPC for selected
BCP-ALL subgroups.
−
10
00
−
10
0
10
0
10
00
10
00
0
1E
5
BCP−ALL RELAPSE
A
P
C
:C
D
12
3−
M
F
I (
m
ed
ia
n
)
DX RX
n = 19
p = <0.001
A
P
C
:C
D
12
3 
(d
el
ta
)
−
1
0
1
−
10
00
−
10
0
10
0
10
00
10
00
0
1E
5
AML RELAPSE
A
P
C
:C
D
12
3−
M
F
I (
m
ed
ia
n
)
DX
(A) (B) (C)
RX
n = 57
p = 0.499
A
P
C
:C
D
12
3 
(d
el
ta
)
−
1
0
1
−
10
00
−
10
0
10
0
10
00
10
00
0
1E
5
AML LSC
A
P
C
:C
D
12
3−
M
F
I (
m
ed
ia
n
)
BLASTS LSC
n = 32
p = 0.875
A
P
C
:C
D
12
3 
(d
el
ta
)
−
1
0
1
FIG. 4. Paired evaluations (diagnosis versus relapse and leukemic blasts vs. leukemic stem cells). Initial diagnosis (DX) versus relapse (RX) for BCP-
ALL patients (A) and AML patients (B). Leukemic blasts versus LSCs in AML patients (C). Black bars indicate increased CD123-MFI while gray bars
indicate decreased CD123-MFI (right vs. left side). Lower panels visualize the delta CD123 expression (after default logicle transformation), thereby
clearly visualizing the magnitude and direction of changes. Reported P-values are based on a paired Mann–Whitney U test.
BRAS ET AL.6
Cytometry Part B: Clinical Cytometry
Number of positive cells can be measured based on
any intensity cut-off, whereby lower cut-offs might
introduce more false-positive cells. Therefore, statistical
tests based on the objectively deﬁned 739 positivity
cut-off were also repeated based on the arbitrarily cho-
sen 1,000 intensity cut-off, which resulted in identical
conclusions as well, thereby ruling out a (strong) inﬂu-
ence of false-positive cells on the ﬁnal conclusions (Ext
Supporting Information 2).
Within the combined EMC-DCOG cohort, the age dis-
tribution of AML and T-ALL patients was skewed
toward pediatric cases (Supporting Information 1),
therefore each analysis including age as statistical
parameter was repeated within EMC cohort (consisting
of consecutive pediatric and adult cases), which
resulted in identical conclusions (Ext Supporting Infor-
mation 3 for CD123-MFI correlations and Ext Support-
ing Information 4 for CD123-PPC correlations).
CONCLUSION AND DISCUSSION
Routine diagnostic evaluation based on highly stan-
dardized immunophenotyping techniques allowed us
to retrospectively evaluate CD123 expression in
846 acute leukemia patients and 1,736 normal popula-
tions. To our best knowledge, this is the ﬁrst time that
samples from so many patients were analyzed in a fully
standardized manner, allowing quantiﬁcation of CD123
expression in acute leukemia.
Extensive validation conﬁrmed assay stability over
time and across laboratories, therefore these results
(including absolute ﬂuorescent intensities) should be
fully reproducible by laboratories using EuroFlow
immunophenotyping protocols and EuroFlow instru-
ment settings. General conclusions (including relative
ﬂuorescent intensities) should be fully reproducible by
any laboratory (also using different protocols and/or
ﬂuorochromes).
Observed minor nonsigniﬁcant changes over time
and across laboratories (Fig. 1) most likely resulted
from lot-to-lot variations and/or technical variation after
cytometer maintenance. Evaluated positive controls
(PDC) feature very strong CD123 expression, therefore,
small changes in expression might be exaggerated by
the nonlinear nature of PMT at high intensities. The
vast majority of evaluated malignancies showed CD123
expression well within the linear region of the PMT,
therefore, it seems unlikely that these nonsigniﬁcant
changes inﬂuenced the overall results.
Our conclusions were based on robust statistical
analysis, whereby various common analysis strategies
resulted in similar conclusions. Conclusions were not
impacted by the chosen measurement (CD123-MFI
vs. CD123-PPC), chosen descriptive statistic (median
vs. mean), chosen CD123 positivity cut-off (739 vs.
1000) nor chosen cohort (EMC cohort vs. EMC-DCOG
cohort).
In general, CD123 was expressed in the vast majority
of AML and BCP-ALL patients, while absent in most T-
ALL patients. Others have indeed shown that CD123 is
only expressed in the minority of T-ALL patients (14).
Within AML patients, CD123 expression was higher in
NPM1 and FLT1-TD mutated patients and lower in cases
in whom the erythroid or megakaryocytic lineage was
affected, conﬁrming previous smaller studies (2,15,16).
FLT3-mutated AML are poor risk patients that therefore
could be prime candidates for CD123-targeting strate-
gies. Within BCP-ALL patients, CD123 expression was
higher in patients with a (high) hyperdiploid karyotype
or the BCR-ABL1 fusion gene, conﬁrming previous
reports as well (2,17).
Interestingly, paired BCP-ALL diagnosis-relapse sam-
ples revealed that CD123 expression at relapse was
considerably higher compared to initial diagnosis, indi-
cating CD123 targeted therapy as an interesting treat-
ment option in relapsed BCP-ALL. Based on available
ﬂow cytometric data, no relation with maturation status
was found, therefore the reason for this higher CD123
expression in relapsed BCP-ALL remains unclear. In
contrast, CD123 expression in paired AML diagnosis-
relapse samples was highly variable, showing either
considerably higher or lower CD123 expression. Vari-
able immunophenotype changes between diagnosis
and relapse in AML have been reported for other
markers as well (18,19).
Flow cytometry-based minimal-residual disease
(MRD) analysis in BCP-ALL is mainly limited due to
lack of leukemia associated immunophenotypes
(LAIPs) and drug-induced antigen modulation (20).
CD123 has a strong rationale toward ﬂow cytometry-
based MRD analysis (20) and contributes signiﬁcantly
to newly identiﬁed LAIPs (20–23).
Interestingly, we observed that the expression of
CD123 was highly comparable for LSC and the remain-
der of leukemic blasts, which is especially of interest as
LSC within AML patients have an inherent resistance to
traditional chemotherapeutics and their persistence fol-
lowing chemotherapy is often considered to be respon-
sible for disease relapse (24,25). In addition, others
have shown that CD123 is expressed on a majority of
AML leukemic stem cells while only on a minority of
the normal hematopoietic stem cells (26), advocating
an interesting therapeutic target for AML treatment.
Taken together, CD123 targeted therapy might be of
high value for CD123 positive AML cases, both at diag-
nosis and at relapse.
One concern for CD123 targeted therapy might be the
relatively high CD123 expression in various normal
populations (eosinophils, neutrophils, plasmacytoid den-
dritic cells), which might lead to eradication of these cells
during therapy. It remains to be seen in clinical trials
how critical this will be with respect to toxicity and safety
for patients. Although ﬁrst studies showed that CD123
therapy is generally well tolerated (27), a recent clinical
trial evaluating the efﬁcacy of Talacotuzumab has been
put on hold for yet unknown reasons.
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Several CD123 therapeutic monoclonal antibodies
have recently been developed and their efﬁcacy is
likely to correlate with CD123 expression levels. How-
ever, it should be emphasized that the expression levels
do not necessarily translate in CD123 antibody therapy
efﬁcacy, as therapy efﬁcacy depends on many factors
as well, including antigen density, antigen distribution,
antigen afﬁnity, internalization rate, association rate,
and dissociation rate (28–30).
Given the recent number of publications regarding
CD123 therapeutic agents and the recent initiation of
various clinical trials, insight in CD123 expression is in
high demand. Altogether, our results provide a trust-
worthy and unique insight into CD123 expression.
Results from previous smaller sized studies were con-
ﬁrmed in a large cohort of patients using standardized
and reproducible methodology. Increased expression
in relapsing BCP-ALL is a novel ﬁnding (and potentially
very interesting for future therapy decisions and MRD
panel design). Our data may facilitate stratiﬁcation of
patients most likely to respond to CD123 targeted ther-
apies and may serve as reference for CD123 expression
in both health and disease.
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